Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05LTJ
|
|||
| Former ID |
DCL001062
|
|||
| Drug Name |
ISIS 325568
|
|||
| Synonyms |
BDBM231666; N-(2-(1H-indol-3-yl)ethyl)-3-(3-thiazol-2-ylureido)benzenesulfonamide (1b)
Click to Show/Hide
|
|||
| Drug Type |
Antisense drug
|
|||
| Indication | Type-2 diabetes [ICD-11: 5A11; ICD-9: 250] | Phase 1 | [1] | |
| Therapeutic Class |
Antisense
|
|||
| Company |
Licensed to Ortho-McNeil, Inc.
|
|||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Glucagon receptor messenger RNA (GCGR mRNA) | Target Info | . | [2] |
| Reactome | Glucagon signaling in metabolic regulation | |||
| G alpha (q) signalling events | ||||
| G alpha (s) signalling events | ||||
| Glucagon-type ligand receptors | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00519727) Safety Study of ISIS 325568 in Healthy Volunteers. U.S. National Institutes of Health. | |||
| REF 2 | Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.